23.06.2013
•
Views
Case Closing and End-of-Treatment Evaluation When patients complete treatment for pulmonary TB, three sputum specimens for AFB and culture, and a chest radiograph should be considered. Although a chest radiograph may be difficult and costly for patients living in remote locations, sputa can be collected and mailed to the ASPHL. PHN case managers should also provide their patients with an End of Treatment Letter and Summary (18.1) documenting treatment. For consultation regarding completion of therapy, end-of-treatment evaluation, or considerations for retreatment, contact the Alaska Tuberculosis Control Officer at 907-269-8000. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Treatment of Tuber culosis Disease 6.25 Revised November 2012
Post-Treatment Evaluation Routine follow-up after completion of therapy is not necessary for patients with M. tuberculosis isolates that are susceptible to all first-line anti-tuberculosis drugs and who received a satisfactory and prompt bacteriologic response to a six- or nine-month treatment regimen that included both isoniazid and rifampin. Post-treatment evaluation is also not required for most patients who have M. tuberculosis isolates resistant to isoniazid only but susceptible to rifampin, pyrazinamide, and ethambutol and have completed 9 months of treatment with all three of these medications. The table below describes the clinician’s responsibilities at completion of therapy for cases in which the organisms are drug-susceptible and drug-resistant. Table 7: GUIDELINES FOR POST-TREATMENT EVALUATION ** Category of Patient Frequency of Post-Treatment Evaluation Drug-susceptible organisms Monoresistance to INH with 6-9 mo. treatment with RIF, PZA, and EMB No reevaluation necessary. Instruct the patient to promptly report the development of any symptoms, particularly prolonged cough, fever, or weight loss. No reevaluation necessary. Instruct the patient to promptly report the development of any symptoms, particularly prolonged cough, fever, or weight loss. INH and RIF resistance 4,8,12,18, and 24 months* RIF or Rifabutin not used in regimen 4,8,12,18, and 24 months* Self-administered treatment regimen 4,8, and 12 months* History of previous treatment, but who have (1) no details available about the treatment, (2) negative sputum cultures, (3) significant changes on CXR, and (4) refuse retreatment No history of previous treatment and who have (1) negative sputum cultures, (2) significant changes on the CXR, and (3) refuse retreatment TB skin test positive and culture negative who are treated empirically because CXR findings are consistent with TB, but who also have other non-TB pulmonary disease. 4,8, and 12 months* 4,8, and 12 months* *Evaluation should include a chest x-ray and the collection of a sputum specimen for smear and culture. Refer for further pulmonary evaluation if no response to anti-TB treatment and/or re-evaluate with a CXR every 3-4 months for 1 year. **Adapted from Clinical Policies and Protocols. Bureau of Tuberculosis Control, New York City Department of Health, 4th Edition, March 2008, page p. 116 A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Treatment of Tuber culosis Disease 6.26 Revised November 2012
-
Page 1 and 2:
Alaska Tuberculosis Program Manual
-
Page 3 and 4:
Purpose............................
-
Page 5 and 6:
Monthly assessment of adherence ...
-
Page 7 and 8:
When to Expand a Contact Investigat
-
Page 9 and 10:
Introduction CONTENTS About the Ala
-
Page 11 and 12:
How to Use This Manual Portable Doc
-
Page 13 and 14:
Printing To access the print dialog
-
Page 15 and 16:
Abbreviations Refer to the list bel
-
Page 17 and 18:
QFT QuantiFERON ® -TB test QFT-G Q
-
Page 19 and 20:
Alaska Statutes and Regulations on
-
Page 21 and 22:
National and State Program Objectiv
-
Page 23 and 24:
Indicator 3 Thorough contact invest
-
Page 25 and 26:
National Standards and Recommendati
-
Page 27 and 28:
Roles and Responsibilities Contact
-
Page 29 and 30:
Local Public Health Agencies Table
-
Page 31 and 32:
Resources and References Resources
-
Page 33 and 34:
Introduction Purpose Use this secti
-
Page 35 and 36:
Contact investigation: Collecting,
-
Page 37 and 38:
Reporting Tuberculosis Detecting an
-
Page 39 and 40:
Prompt reporting (prior to culture
-
Page 41 and 42:
Use the Infectious Disease Report F
-
Page 43 and 44:
Data Collection Forms The following
-
Page 45 and 46:
Genotyping Genotyping is a useful t
-
Page 47 and 48:
References 1 ATS, CDC, IDSA. Contro
-
Page 49 and 50:
Introduction Purpose Use this secti
-
Page 51 and 52:
child or a person acting on behalf
-
Page 53 and 54:
When to Conduct Targeted Testing Al
-
Page 55 and 56:
Alaska Program Standards for Health
-
Page 57 and 58:
B Notifications CONTENTS Introducti
-
Page 59 and 60:
Table 1: NUMBERS OF FOREIGN-BORN PE
-
Page 61 and 62:
chest radiograph and if sputum AFB
-
Page 63 and 64:
Follow-up of B1 and B2 Tuberculosis
-
Page 65 and 66:
Evaluation of B1, B2, and B Tubercu
-
Page 67 and 68:
Treatment Prescribe medications as
-
Page 69 and 70:
12 Centers for Disease Control and
-
Page 71 and 72:
Introduction Purpose Use this secti
-
Page 73 and 74:
Tuberculosis Classification System
-
Page 75 and 76:
Table 2: PERSONS AT HIGH RISK FOR T
-
Page 77 and 78:
Table 3: WHEN TO SUSPECT PULMONARY
-
Page 79 and 80:
Diagnosis of Tuberculosis Disease T
-
Page 81 and 82:
1. Exposure to Infectious TB: Ask p
-
Page 83 and 84:
Physical Examination A physical exa
-
Page 85 and 86:
For more information on chest radio
-
Page 87 and 88:
Laboratories should report positive
-
Page 89 and 90:
Guidelines for preventing the trans
-
Page 91 and 92:
50 CDC. National plan for reliable
-
Page 93 and 94:
Introduction Purpose The overall go
-
Page 95 and 96:
Basic Treatment Principles Follow t
-
Page 97 and 98:
Treatment Regimens and Dosages Use
-
Page 99 and 100:
Table 3: FOUR TREATMENT REGIMENS FO
-
Page 101 and 102:
† 4 Table 4: DOSES*OF FIRST-LINE
-
Page 103 and 104:
Figure 1:TREATMENT ALGORITHM FOR DR
-
Page 105 and 106:
a. In remote locations in Alaska, m
-
Page 107 and 108:
Antituberculosis Drug Rifampin (RIF
-
Page 109 and 110:
Antituberculosis Drug Rifapentine (
-
Page 111 and 112:
Reporting Reactions The table below
-
Page 113 and 114:
Response to Treatment For consultat
-
Page 115:
Figure 2: MANAGEMENT OF TREATMENT I
-
Page 119 and 120:
Treatment in Special Situations Tre
-
Page 121 and 122:
Resources For consultation regardin
-
Page 123 and 124:
with an increase in overall complet
-
Page 125 and 126:
Liver Disease Management of TB in p
-
Page 127 and 128:
After the initial phase (first two
-
Page 129 and 130:
Extrapulmonary Tuberculosis The bas
-
Page 131 and 132:
Resources and References Resources
-
Page 133 and 134:
Diagnosis of Latent Tuberculosis In
-
Page 135 and 136:
Forms All required and recommended
-
Page 137 and 138:
High-Risk Groups Certain factors id
-
Page 139 and 140:
Diagnosis of Latent Tuberculosis In
-
Page 141 and 142:
continually exposed to populations
-
Page 143 and 144:
Administration of the Tuberculin Sk
-
Page 145 and 146:
See “Two-Step Tuberculin Skin Tes
-
Page 147 and 148:
See “Live-Virus Vaccines” under
-
Page 149 and 150:
For more information on IGRAs and t
-
Page 151 and 152:
Table 5: TARGETED TESTING FOR LATEN
-
Page 153 and 154:
Resources and References Resources
-
Page 155 and 156:
Treatment of Latent Tuberculosis In
-
Page 157 and 158:
Policy Detailed information on the
-
Page 159 and 160:
Window period prophylaxis is treatm
-
Page 161 and 162:
Regimens Identify an appropriate re
-
Page 163 and 164:
Dosages Once the appropriate regime
-
Page 165 and 166:
Side Effects and Adverse Reactions
-
Page 167 and 168:
If a patient reports to a healthcar
-
Page 169 and 170:
Antituberculosis Drug Rifampin (RIF
-
Page 171 and 172:
DOT is strongly encouraged for thos
-
Page 173 and 174:
Table 7 describes the duration of t
-
Page 175 and 176:
Alcoholism Alcohol-Related Treatmen
-
Page 177 and 178:
Medication Administration and Pharm
-
Page 179 and 180:
National Tuberculosis Controllers A
-
Page 181 and 182:
24 CDC . “Recommendations for Use
-
Page 183 and 184:
Diagnosis and Treatment of Latent T
-
Page 185 and 186:
All children suspected or diagnosed
-
Page 187 and 188:
Latent Tuberculosis Infection (LTBI
-
Page 189 and 190:
History of BCG vaccination is not a
-
Page 191 and 192:
Because of their higher specificity
-
Page 193 and 194:
Table 3: COUNTRIES AND AREAS WITH A
-
Page 195 and 196:
Treatment of Latent TB Infection (L
-
Page 197 and 198:
For consultation regarding the trea
-
Page 199 and 200:
Monitoring DOT is mandatory for INH
-
Page 201 and 202:
For young infants, some experts rec
-
Page 203 and 204:
TABLE 8: SIGNS AND SYMPTOMS OF PULM
-
Page 205 and 206:
Treatment of Tuberculosis Basic pri
-
Page 207 and 208:
Regime n 1 2 3 ❺ Table 10: FOUR T
-
Page 209 and 210:
† 35 Table 11: DOSES*OF FIRST-LIN
-
Page 211 and 212:
Monitoring Response to Treatment Ch
-
Page 213 and 214:
Child Care and Schools: Children wi
-
Page 215 and 216:
Other TB medications are not commer
-
Page 217 and 218:
10 Centers for Disease Control and
-
Page 219 and 220:
Case Management CONTENTS Introducti
-
Page 221 and 222:
patient-centered approach to case m
-
Page 223 and 224:
Alaska TB Program: Timeline for the
-
Page 225 and 226:
For assistance with language issues
-
Page 227 and 228:
Ascertain the extent of TB illness
-
Page 229 and 230:
medical/health problem. The date of
-
Page 231 and 232:
necessary to teach people how to ta
-
Page 233 and 234:
Treatment Plan Components Recommend
-
Page 235 and 236:
Implementation Activities To begin
-
Page 237 and 238:
o Indicate the number of doses prov
-
Page 239 and 240:
Review the status of the contact in
-
Page 241 and 242:
For more information, see the “Di
-
Page 243 and 244:
importance of continued treatment a
-
Page 245 and 246:
5. Review information with the prov
-
Page 247 and 248:
Completion of Therapy The case mana
-
Page 249 and 250:
Case Closures Other than Completion
-
Page 251 and 252:
Conduct a case management meeting o
-
Page 253 and 254:
Biweekly (BIW) doses of TB medicati
-
Page 255 and 256:
Use DOT with other measures such as
-
Page 257 and 258:
It is important not to send a mixed
-
Page 259 and 260:
Medical Orders Progressive Interven
-
Page 261 and 262:
CDC. Module 9: “Patient Adherence
-
Page 263 and 264:
36 New Jersey Medical School Nation
-
Page 265 and 266:
75 CDC. Module 9: patient adherence
-
Page 267 and 268:
Introduction Purpose A contact inve
-
Page 269 and 270:
For roles and responsibilities, ref
-
Page 271 and 272:
Decision to Initiate a Contact Inve
-
Page 273 and 274:
chest radiographic findings that ar
-
Page 275 and 276:
In general, a contact investigation
-
Page 277 and 278:
Time Frames for Contact Investigati
-
Page 279 and 280:
Circumstances unique to Alaska may
-
Page 281 and 282:
Circumstances unique to Alaska may
-
Page 283 and 284:
Activity Purpose Maximum Time Inter
-
Page 285 and 286:
Infectious Period Determine the inf
-
Page 287 and 288:
In general, for the purposes of con
-
Page 289 and 290:
General Guidelines for Interviewing
-
Page 291 and 292:
Healthcare workers should remember
-
Page 293 and 294:
Index Patient with Positive Acid-Fa
-
Page 295 and 296:
Index Patient with Negative Acid-Fa
-
Page 297 and 298:
Contact Evaluation, Treatment, and
-
Page 299 and 300:
Definition of abbreviations: HIV =
-
Page 301 and 302:
Note: An IGRA may be used in place
-
Page 303 and 304:
When to Expand a Contact Investigat
-
Page 305 and 306:
Figure 7: EVALUATION, TREATMENT, AN
-
Page 307 and 308:
CDC’s “Framework of Program Eva
-
Page 309 and 310:
Definitions of abbreviations: AIDS
-
Page 311 and 312:
elease assay; LTBI = latent tubercu
-
Page 313 and 314:
officials to distinguish between di
-
Page 315 and 316:
References 1 ATS, CDC, IDSA. Contro
-
Page 317 and 318:
44 CDC, NTCA. Guidelines for the in
-
Page 319 and 320:
Introduction Purpose Use this secti
-
Page 321 and 322:
Available Laboratory Tests Table 2:
-
Page 323 and 324:
Table 3: PCR Testing Algorithm and
-
Page 325 and 326:
Table 4: SPECIMEN COLLECTION METHOD
-
Page 327 and 328:
5. If possible, send the specimen o
-
Page 329 and 330:
Specimen Shipment There are three m
-
Page 331 and 332:
Resources and References Resources
-
Page 333 and 334:
Patient Education CONTENTS Introduc
-
Page 335 and 336:
treatment, common side-effects of m
-
Page 337 and 338:
Education Topics During the initial
-
Page 339 and 340:
10. Explain the signs and symptoms
-
Page 341 and 342:
Patient Education Materials Get th
-
Page 343 and 344:
References 1 CDC. Module 4: treatme
-
Page 345 and 346:
Introduction Purpose Use this secti
-
Page 347 and 348:
National Guidelines The following g
-
Page 349 and 350:
Transfer Notifications CONTENTS Int
-
Page 351 and 352:
For roles and responsibilities, ref
-
Page 353 and 354:
Follow-Up Type When to Initiate Not
-
Page 355 and 356:
Action Transfers Within Alaska Tran
-
Page 357 and 358:
Provide the patient with a. A copy
-
Page 359 and 360:
References 1 CDC. International not
-
Page 361 and 362:
Infection Control CONTENTS Introduc
-
Page 363 and 364:
of TB infection control principles
-
Page 365 and 366:
Administrative Activities 13 Key ac
-
Page 367 and 368:
Personal Respiratory Protection Alt
-
Page 369 and 370:
For regulations in your area, refer
-
Page 371 and 372:
Employee Health All employees, phys
-
Page 373 and 374:
Figure 1: TWO STEP TESTING AND FOLL
-
Page 375 and 376:
Isolation To reduce disease transmi
-
Page 377 and 378:
Table 4: CRITERIA FOR PATIENTS TO B
-
Page 379 and 380:
When to Initiate Airborne Infection
-
Page 381 and 382:
Confirmed Tuberculosis Disease A pa
-
Page 383 and 384:
Multidrug-Resistant Tuberculosis Di
-
Page 385 and 386:
Environmental Controls in the Patie
-
Page 387 and 388:
Return to Work, School, or Other So
-
Page 389 and 390:
Tuberculosis Infection Control in P
-
Page 391 and 392:
Transportation Vehicles To prevent
-
Page 393 and 394:
7 CDC. Guidelines for preventing th
-
Page 395 and 396:
Forms: Alaska State Public Health L
-
Page 397 and 398:
ALASKA STATE PUBLIC HEALTH LABORATO
-
Page 399 and 400:
Anchorage Alaska State Public Healt
-
Page 401 and 402:
INDEX CASE INFORMATION Name: DOB: /
-
Page 403 and 404:
CONTACT Name: Tuberculosis Contact
-
Page 405 and 406:
Directly Observed Therapy (DOT) Cal
-
Page 407 and 408:
B. Documents patient care activitie
-
Page 409 and 410:
Alaska TB Program Section of Epidem
-
Page 411 and 412:
Treatment Summary for Active TB Nam
-
Page 413 and 414:
Interjurisdictional Tuberculosis No
-
Page 415 and 416:
! !"#$%&'%()*(+#(,"-./0'1$%+'.,)()/
-
Page 417 and 418:
! B!9:(78;7)3702D!! ! 3"#$%&%''98#5
-
Page 419 and 420:
! ?"#51)09/02!H0/.!9:(78;7)37028!/'
-
Page 421 and 422:
Latent Tuberculosis Infection (LTBI
-
Page 423 and 424:
Alaska Tuberculosis Program 9210 Va
-
Page 425 and 426:
Instructions for Collecting Sputum
-
Page 427 and 428:
TB Case Management Information Requ
-
Page 429 and 430:
Table 1: First-line anti-tuberculos
-
Page 431 and 432:
Return the fax to the Drug Room (90
-
Page 433 and 434:
Stock Orders: A small supply of
-
Page 435 and 436:
TB/LTBI Medication Return Form Reas
-
Page 437 and 438:
TB/LTBI Stock Medication Request FA
-
Page 439 and 440:
TB Medication Dose Monitoring Regim
-
Page 441 and 442:
TB Medication Dose Monitoring Regim
-
Page 443 and 444:
ALASKA DEPARTMENT OF HEALTH AND SOC
-
Page 445:
Tuberculosis Discharge Planning Che
-
Page 448 and 449:
PART 2: 8. Have you ever been told
-
Page 450 and 451:
Tuberculosis Treatment Contract Dep
-
Page 452 and 453:
Statutes and Regulations Contents I
-
Page 454 and 455:
Regulations Infection Control 7 AAC
-
Page 456 and 457:
place of work is remote from patien
-
Page 458 and 459:
(2) the child or a person acting on
-
Page 460 and 461:
Glossary acid-fast bacilli (AFB): M
-
Page 462 and 463:
eaction size on a later test, which
-
Page 464 and 465:
disseminated TB: See miliary TB. dr
-
Page 466 and 467:
immunocompromised and immunosuppres
-
Page 468 and 469:
include medical history and TB symp
-
Page 470 and 471:
thousands to millions of copies of
-
Page 472 and 473:
secondary (TB) case: A new case of
-
Page 474:
eproducing TB organisms from respir
Change language